Literature DB >> 22989004

Deep sequencing does not reveal additional transmitted mutations in patients diagnosed with HIV-1 variants with single nucleoside reverse transcriptase inhibitor resistance mutations.

M Pingen1, M E van der Ende, A M Wensing, A el Barzouhi, B B Simen, M Schutten, C A B Boucher.   

Abstract

OBJECTIVES: The aim of the study was to gain more insight into the relationship between transmitted singletons found at HIV diagnosis by population sequencing and the possible presence of clinically relevant viral minorities containing additional resistance mutations.
METHODS: We studied the viral quasispecies and therapy response in 10 individuals with transmitted single nucleoside reverse transcriptase inhibitor (NRTI)-related resistance mutations as detected by population sequencing.
RESULTS: Ultra-deep pyrosequencing did not reveal additional drug-resistance mutations in nine of 10 patients. In these nine patients, no breakthrough with resistant viruses was observed despite the use of low genetic nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens in the majority of patients.
CONCLUSIONS: These data suggest that viral minority variants containing additional resistance mutations may be rare in patients with transmitted NRTI singletons in the Netherlands. Larger studies are required to confirm these findings and to determine the therapeutic consequences.
© 2012 British HIV Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22989004     DOI: 10.1111/j.1468-1293.2012.01037.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  6 in total

1.  Deep Sequencing of HIV-1 RNA and DNA in Newly Diagnosed Patients with Baseline Drug Resistance Showed No Indications for Hidden Resistance and Is Biased by Strong Interference of Hypermutation.

Authors:  Kenny Dauwe; Delfien Staelens; Leen Vancoillie; Virginie Mortier; Chris Verhofstede
Journal:  J Clin Microbiol       Date:  2016-04-13       Impact factor: 5.948

2.  Low-Abundance Drug-Resistant HIV-1 Variants in Antiretroviral Drug-Naive Individuals: A Systematic Review of Detection Methods, Prevalence, and Clinical Impact.

Authors:  Herbert A Mbunkah; Silvia Bertagnolio; Raph L Hamers; Gillian Hunt; Seth Inzaule; Tobias F Rinke De Wit; Roger Paredes; Neil T Parkin; Michael R Jordan; Karin J Metzner
Journal:  J Infect Dis       Date:  2020-04-27       Impact factor: 5.226

3.  Comparison of 454 Ultra-Deep Sequencing and Allele-Specific Real-Time PCR with Regard to the Detection of Emerging Drug-Resistant Minor HIV-1 Variants after Antiretroviral Prophylaxis for Vertical Transmission.

Authors:  Andrea Hauser; Claudia Kuecherer; Andrea Kunz; Piotr Wojtek Dabrowski; Aleksandar Radonić; Andreas Nitsche; Stefanie Theuring; Norbert Bannert; Julius Sewangi; Paulina Mbezi; Festo Dugange; Gundel Harms; Karolin Meixenberger
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

4.  Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity.

Authors:  Marieke Pingen; Annemarie M J Wensing; Katrien Fransen; Annelies De Bel; Dorien de Jong; Andy I M Hoepelman; Emmanouil Magiorkinis; Dimitrios Paraskevis; Maja M Lunar; Mario Poljak; Monique Nijhuis; Charles A B Boucher
Journal:  Retrovirology       Date:  2014-11-29       Impact factor: 4.602

5.  Characterization of HIV-1 Near Full-Length Proviral Genome Quasispecies from Patients with Undetectable Viral Load Undergoing First-Line HAART Therapy.

Authors:  Brunna M Alves; Juliana D Siqueira; Marianne M Garrido; Ornella M Botelho; Isabel M Prellwitz; Sayonara R Ribeiro; Esmeralda A Soares; Marcelo A Soares
Journal:  Viruses       Date:  2017-12-19       Impact factor: 5.048

6.  Prevalence and persistence of transmitted drug resistance mutations in the German HIV-1 Seroconverter Study Cohort.

Authors:  Patrycja Machnowska; Karolin Meixenberger; Daniel Schmidt; Heiko Jessen; Heribert Hillenbrand; Barbara Gunsenheimer-Bartmeyer; Osamah Hamouda; Claudia Kücherer; Norbert Bannert
Journal:  PLoS One       Date:  2019-01-16       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.